Literature DB >> 14725676

Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature.

J C Blair1, C Camacho-Hübner, F Miraki Moud, S Rosberg, C Burren, S Lim, P E Clayton, R Bjarnason, K Albertsson-Wikland, M O Savage.   

Abstract

OBJECTIVE: Abnormalities in the GH-IGF-I axis, consistent with GH insensitivity (GHI), have been reported in some patients with idiopathic short stature (ISS). The standard IGF-I generation test (IGFGT) has not demonstrated mild GHI in subjects with ISS. The aim of this study was to investigate the GH-IGF-I axis in ISS by performing standard and novel low-dose IGFGTs together with determination of spontaneous GH secretion. PATIENTS AND METHODS: Twenty-one (17 male) prepubertal children with ISS, mean age 8.3 years (4.5-12.2), mean height -3.48 SD (-5.40 to -1.79), mean peak GH to provocation with glucagon/clonidine 32.3 mU/l (14.1-66.0) were studied. Serum IGF-I and IGFBP-3 levels were measured during standard (GH 0.033 mg/kg/day x 4) and low (GH 0.011 mg/kg/day x 4) dose IGFGTs at 0, 12, 36 and 84 h. The low-dose IGFGT was performed in seven naive GH-deficient patients (4 male), mean age 8.5 years (range 4.1-11.1). Determination of spontaneous 24-h GH secretion was performed in the 21 ISS patients.
RESULTS: Basal IGF-I and IGFBP-3 standard deviation scores (SDS) in ISS patients were -1.39 (-2.4-1.16) and -0.45 (-1.13-0.38), respectively, IGF-I being lower than IGFBP-3 (P < 0.0001). IGF-I increased in the standard IGFGT at 12 h (P < 0.005), 36 h (P < 0.001) and 84 h (P < 0.001); maximal increment 1.54 (-0.32-3.48), and in the low-dose test at 12 h (P < 0.005), 36 h (P < 0.001) and 84 h (P < 0.005); maximal increment 0.53 (0.08 to -1.23). IGFBP-3 SDS increased in the standard IGFGT at 36 h (P < 0.01) and 84 h (P < 0.001); maximal increment 0.72 (-0.44-1.96), and in the low-dose test at 84 h (P < 0.005); maximal increment 0.33 (-0.08-0.87). Five/19 patients with an IGF-I response > 2 x coefficient of variation (CV) of assay in the standard test failed to respond in the low-dose test, suggestive of mild GHI. In GH-deficient patients, IGF-I increased at each time point (P < 0.05) and IGFBP-3 at 36 h (P < 0.05). Mean GH secretion, expressed in SDS, compared with 66 normal stature controls was: basal GH -0.48 (-0.84-0.93), height of GH peaks compared with zero -0.36 (-1.26-1.51) (both P < 0.05), total GH secretion -0.76 (-1.22-0.42), total GH secretion above baseline -0.67 (-1.21-0.94) (both P < 0.01).
CONCLUSIONS: In children with ISS, basal IGF-I and IGFBP-3 SDS values were below the mean, IGF-I showing a greater response in both IGFGTs. In the standard IGFGT, the IGF-I increase at 36 h was equal to that at 84 h. The low-dose IGFGT, in combination with the standard test, may identify patients with mild GHI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14725676     DOI: 10.1046/j.1365-2265.2004.01957.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  IGF-I and IGF Binding Protein-3 Generation Tests and Response to Growth Hormone in Children with Silver-Russell Syndrome.

Authors:  Izabel C R Beserra; Márcia G Ribeiro; Paulo F Collett-Solberg; Mário Vaisman; Marília M Guimarães
Journal:  Int J Pediatr Endocrinol       Date:  2010-12-27

Review 2.  Insulin-like growth factor- I and factors affecting it in thalassemia major.

Authors:  Ashraf T Soliman; Vincenzo De Sanctis; Rania Elalaily; Mohamed Yassin
Journal:  Indian J Endocrinol Metab       Date:  2015 Mar-Apr

3.  Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height.

Authors:  Daniel B Hawcutt; Jennifer Bellis; Victoria Price; Anne Povall; Paul Newland; Paul Richardson; Matthew Peak; Jo Blair
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

4.  GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome.

Authors:  Jovanna Dahlgren; Kerstin Albertsson-Wikland
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-09       Impact factor: 5.555

5.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

Review 6.  Compound heterozygosity for two GHR missense mutations in a patient affected by Laron Syndrome: a case report.

Authors:  Stefania Moia; Daniele Tessaris; Silvia Einaudi; Luisa de Sanctis; Gianni Bona; Simonetta Bellone; Flavia Prodam
Journal:  Ital J Pediatr       Date:  2017-10-12       Impact factor: 2.638

Review 7.  The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders.

Authors:  Werner F Blum; Abdullah Alherbish; Afaf Alsagheir; Ahmed El Awwa; Walid Kaplan; Ekaterina Koledova; Martin O Savage
Journal:  Endocr Connect       Date:  2018-05-03       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.